Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | NOS2 | P35228 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | C3AR1 | Q16581 | 4/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NRP1 | O14786 | 4/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27898034 | 1.00 | CYP2C19 (0.65) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29603738 | 0.97 | CYP1A2 (0.61) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL30391184 | 0.97 | CYP1A2 (0.61) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL28409679 | 0.97 | CYP1A2 (0.61) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29356389 | 0.97 | CYP1A2 (0.61) | CYP2C19NOS2CYP1A2GLATSHR | |
| Hydrochloric Acid SCHEMBL1880117 | 0.94 | CYP1A2 (0.58) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29351011 | 0.93 | CYP1A2 (0.56) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29353243 | 0.93 | CYP1A2 (0.56) | CYP2C19NOS2CYP1A2GLATSHR | |
| Acetic Acid SCHEMBL29358131 | 0.93 | NPY1R (0.59) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL31470824 | 0.93 | CYP1A2 (0.56) | CYP2C19NOS2CYP1A2GLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 946 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260071252-A1 | REVERSIBLE NANOPARTICLE AGGREGATES AND METHODS FOR DETECTING PROTEASES | UNIV CALIFORNIA (US) | 2026-03-12 | — | — | US | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250282838-A1 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | OTHAIR PROTHENA LIMITED (IE) | 2025-09-11 | — | — | US | claimed |
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2025-09-04 | — | — | US | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | claimed |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2022-05-17 | — | — | US | claimed |
| CN-114450294-A | Polypeptide with MMP2 inhibitory effect | 大正制药株式会社 | 2022-05-06 | — | — | CN | claimed |
| US-20220135622-A1 | ANTIBACTERIAL PEPTIDES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-05-05 | — | — | US | claimed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | claimed |
| WO-2022060488-A1 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | OTHAIR PROTHENA LIMITED (IE) | 2022-03-24 | — | — | WO | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| US-20220073898-A1 | Tandem Protein Expression | NOVOZYMES A/S (DK) | 2022-03-10 | — | — | US | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071252-A1 | REVERSIBLE NANOPARTICLE AGGREGATES AND METHODS FOR DETECTING PROTEASES | IDUA, XPNPEP1, CHIA | CYP2C19 4777/4885NOS2 2488/4885CYP1A2 4770/4885 |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | CYP2C19 3914/4885NOS2 2151/4885CYP1A2 4637/4885 |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | SLC10A1, CD47, SELPLG | CYP2C19 1174/4885NOS2 4033/4885CYP1A2 2974/4885 |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VIP, AREG, MIF | CYP2C19 3914/4885NOS2 2151/4885CYP1A2 4637/4885 |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | MMP3, PEPD, MMP9 | CYP2C19 2292/4885NOS2 1540/4885CYP1A2 2360/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | CYP2C19 1432/4885NOS2 1854/4885CYP1A2 2885/4885 |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SLC7A1, KARS1, LNPEP | CYP2C19 348/4885NOS2 1592/4885CYP1A2 1190/4885 |
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | CYP2C19 4701/4885NOS2 2257/4885CYP1A2 4835/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | CYP2C19 3681/4885NOS2 1504/4885CYP1A2 4565/4885 |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | CYP2C19 2796/4885NOS2 3621/4885CYP1A2 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.